Salute e Benessere

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic…

Click here to view the custom infographic of the Calidi Biotherapeutics Inc. editorial. Clickhere to view the custom infographic of the Calidi Biotherapeutics Inc. editorial. Sustained Investment in Research, Development Cancer remains one of the most devastating health challenges facing the globe today, responsible for about one in six deaths worldwide ( https://ibn.fm/ZzZHC ). The most common cancer types worldwide include lung cancer (accounting for around 2.2 million new cases...
PR Newswire
07/07/2025

Medicines for Poland Announces: Without pharmaceutical factories Europe will…

The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of medicines in Ukraine. Medicines for Poland: The European Commission should put in place real support for the existing pharma industry in Europe to enable relocation of the production of critical medicines and their ingredients back to the EU, with a focus on Central and Eastern Europe as an area with...
Nasdaq GlobeNewswire
07/07/2025

SciBase: A new important customer in the US, Palm Beach Dermatology Group, has…

Melanoma, the deadliest form of skin cancer, remains a serious and growing public health concern in the United States. According to the American Cancer Society, an estimated 190,000 new cases of melanoma will be diagnosed in the U.S. in 2025. Tragically, approximately 8,290 people are expected to die from melanoma this year. However, early detection is key - when found at an early stage, melanoma has an almost 100% cure rate. Melanoma, the deadliest form of skin cancer, remains a serious and...
PR Newswire
07/07/2025

Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential…

Ingelheim, Germany, July 7, 2025– Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study ( NCT06962839 ). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision in people with diabetic macular edema (DME). 1 DME is a leading cause of vision loss in people with diabetes. It affects more than 21 million people globally—impacting up to 10% of those living with diabetes. 2,3,4Current treatments...
Nasdaq GlobeNewswire
07/07/2025

Hisense Makes the Home Smarter to Help Fans 'Own the Moment' During FIFA Club…

In the kitchen, the PureFlat Smart Series Refrigerator acts as a central hub for modern households. Its 21-inch smart screen offers recipe suggestions, message board, and food inventory tracking. Independent cooling zones and antibacterial protection ensure food stays fresh and safe, while the ConnectLife APP allows remote control of settings and alerts, giving users peace of mind and uninterrupted enjoyment. In the kitchen, the PureFlat Smart Series Refrigerator acts as a central hub for...
PR Newswire
07/07/2025

One of the largest multi-region healthcare systems in the US expands enterprise…

The pathology module allows pathologists to review and collaborate around cases digitally as well as benefit from AI tools. The digital workflow provides instant and, when needed, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes. With their pathologists and radiologists now sharing a unified system, it will pave the way for integrated diagnostics, which makes collaboration across different specialties more effective. The...
PR Newswire
07/07/2025

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions…

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for EuropeA new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if biosolutions are...
Nasdaq GlobeNewswire
07/07/2025

Eleva administers first dose of its Factor H biological treatment in…

First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patientsFreiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company’s Factor H (CPV-104) program in C3-Glomerulopathy (C3G)...
Nasdaq GlobeNewswire
07/07/2025

ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Denison is Professor of Clinical Neurosciences at the University of Oxford and was previously Vice President of Research and Core Technologies at Medtronic. He is a co-founder and Chief Engineer of neurotechnology company Amber Therapeutics.ONWARD Co-Founder Professor Gregoire Courtine will continue to serve as Science Advisor. He will depart the Board of...
Nasdaq GlobeNewswire
07/07/2025

JUICE PLUS LAUNCHES SUPERFOOD POWDER: A POWERHOUSE OF PLANT-BASED NUTRITION IN…

Superfood Powder is a delicious blend designed to support the immune system[1], oxidative stress protection[2], skin health[3], dental health[4] and more. A vibrant fusion of greens, reds and purples – enhanced with plant-based vitamins and phytonutrients. Each pre-portioned stick pack boasts an unmatched taste* while ensuring maximum convenience, allowing busy individuals to get a delicious daily dose of plant-based nutrition anytime. Simply mix with 300ml of water , stir well and drink! ...
PR Newswire
07/07/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 06/30/2025100,325,22989,428,630 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
04/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market…
Actusnews Wire
04/07/2025

Wearable EEG Devices Market Size to Grow by USD 695.51 million by 2031…

To explore the valuable insights in the Wearable EEG Devices Market report, you can easily download a sample PDF of the report. -https://www.theinsightpartners.com/sample/TIPRE00007291 To explore the valuable insights in the Wearable EEG Devices Market report, you can easily download a sample PDF of the report. -https://www.theinsightpartners.com/sample/TIPRE00007291 This is in contrast to traditional EEG setups, which are usually restricted to hospital or clinical contexts and need...
PR Newswire
04/07/2025

$0.71 Billion by 2032: Why Digital Stethoscopes Are Transforming Modern…

The global digital stethoscopes market, valued at US$0.49 billion in 2025, is projected to grow at a robust CAGR of 5.5%, reaching US$0.71 billion by 2032. This growth is fueled by the increasing burden of chronic cardiovascular and respiratory diseases, the rise of telemedicine, and the demand for remote patient monitoring (RPM). As healthcare evolves toward decentralization and digitization, digital stethoscopes are becoming essential tools—not just for diagnosis, but for real-time care…
PR Newswire
04/07/2025

DoH, USCF and IGI Explore Establishing the World's first-of-their kind Centres…

Genome surgery is an experimental medical technique aimed at modifying or replacing faulty genes within cells to treat or prevent diseases. This is achieved through personalised genetic therapies or by using advanced technologies such as CRISPR, which can be tailored specifically to each patient based on their unique genetic mutations. Genome surgery is an experimental medical technique aimed at modifying or replacing faulty genes within cells to treat or prevent diseases. This is achieved...
PR Newswire
04/07/2025

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving…

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera’s Scientific Advisory Board.Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.In collaboration with PolTREG and leading U.S. academic centers, Immuthera will be developing a...
Nasdaq GlobeNewswire
04/07/2025

Virbac : Declaration of the number of shares and voting rights 06/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsJune, 30 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
04/07/2025

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase…

PRESS RELEASEMASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFITParis, July 4, 2025, 8am CETAB Science SA(Euronext - FR0010557264 - AB) today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer (study AB22007) has been authorized by FDA and EMA (harmonized protocol...
Nasdaq GlobeNewswire
04/07/2025

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneursThe founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapiesCommittee representatives presented the award and the EUR 100,000 cash prize on Thursday, July 3, 2025 Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee...
Nasdaq GlobeNewswire
04/07/2025

Orion publishes Half-Year Financial Report for January–June 2025 and holds a…

ORION CORPORATIONPRESS RELEASE4 JULY 2025 at 09.00 EEST Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 Orion will publish Half-Year Financial Report for January–June 2025 on Friday, 18 July 2025 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website atwww.orionpharma.com/investorsafter publishing. Webcast and conference call A webcast...
Nasdaq GlobeNewswire
04/07/2025

Notification for the purposes of article 13 of the Luxembourg law of 11 January…

Luxembourg (July 3, 2025)– Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.
Nasdaq GlobeNewswire
04/07/2025

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the…

Key Takeaways from the GPRC5D-directed Therapies Market Report Key Takeaways from the GPRC5D-directed Therapies Market Report Discover which indication is expected to grab the major GPRC5D-directed therapies market share @ GPRC5D-directed Therapies Market Report GPRC5D-directed Therapies Market Dynamics The GPRC5D-directed therapies market is emerging as a significant focus within the landscape of multiple myeloma treatment. GPRC5D is an orphan receptor predominantly expressed...
PR Newswire
03/07/2025

Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen…

Corporate Updates Corporate Updates Resignation of Director and Executive Chairman Ron Mayronhas resigned as Executive Chairman and a Director of the Company effectiveJuly 1, 2025. Mr. Mayron will remain with the Company for three additional months as a Special Consultant for the Company. In his place, Iris Bincovich, a current Director of the Company, will be temporarily holding the position of Chair of the Company. Iris Bincovich, Chief Executive Officer and Chair of the...
PR Newswire
03/07/2025

Spineway : GMED approval for new production line dedicated to ESP prostheses -…

Press release Ecully, July 3, 2025 – 6:30 p.m. SPINEWAYGMED approval for new production line dedicated to ESP prosthesesFirst production of LP-ESP intervertebral disc prostheses Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has receivedGMED(French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral disc prostheses...
Nasdaq GlobeNewswire
03/07/2025
Altri  Comunicati